Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab—a report from the BELOB trial

BACKGROUND. The current method for assessing progressive disease (PD) in glioblastoma is according to the Response Assessment in Neuro-Oncology (RANO) criteria. Bevacizumab-treated patients may show pseudo-response on postcontrast T1-weighted (T1w) MRI, and a more infiltrative non-enhancing growth p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Gahrmann, Renske, van den Bent, Martin, van der Holt, Bronno, Vernhout, René Michel, Taal, Walter, Vos, Maaike, de Groot, Jan Cees, Beerepoot, Laurens Victor, Buter, Jan, Flach, Zwenneke Hendrieke, Hanse, Monique, Jasperse, Bas, Smits, Marion
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5464446/
https://ncbi.nlm.nih.gov/pubmed/28204639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now311
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados